ADC Therapeutics SA Debt to Equity Ratio 2019-2023 | ADCT
Current and historical debt to equity ratio values for ADC Therapeutics SA (ADCT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. ADC Therapeutics SA debt/equity for the three months ending March 31, 2023 was 2.57.
| ADC Therapeutics SA Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$0.43B |
$0.04B |
11.41 |
| 2022-12-31 |
$0.44B |
$0.09B |
4.96 |
| 2022-09-30 |
$0.43B |
$0.11B |
4.08 |
| 2022-06-30 |
$0.41B |
$0.12B |
3.51 |
| 2022-03-31 |
$0.42B |
$0.16B |
2.58 |
| 2021-12-31 |
$0.45B |
$0.17B |
2.72 |
| 2021-09-30 |
$0.45B |
$0.19B |
2.41 |
| 2021-06-30 |
$0.22B |
$0.24B |
0.90 |
| 2021-03-31 |
$0.16B |
$0.30B |
0.55 |
| 2020-12-31 |
$0.18B |
$0.34B |
0.53 |
| 2020-09-30 |
$0.15B |
$0.38B |
0.39 |
| 2020-06-30 |
$0.18B |
$0.20B |
0.90 |
| 2020-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-12-31 |
$0.02B |
$0.13B |
0.19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.192B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
